Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070109 · ClinicalTrials.gov registry record · Phase 2
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
A Phase 2 study of Recurrent Ewing Sarcoma and Recurrent Childhood Rhabdomyosarcoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 14
- Study locations
NCT00070109: Completed Phase 2 study of Recurrent Ewing Sarcoma and Recurrent Childhood Rhabdomyosarcoma, sponsored by Children's Oncology Group.
NCT00070109 is a Phase 2 study of Recurrent Ewing Sarcoma and Recurrent Childhood Rhabdomyosarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 50 participants, below the 188-participant average among 9 other Recurrent Ewing Sarcoma trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070109, a Phase 2 study of Recurrent Ewing Sarcoma and Recurrent Childhood Rhabdomyosarcoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
Primary Outcome
Any patient who is enrolled and receives at least one dose of trabectedin will be considered evaluable for response if the individual receives at least one dose of trabectedin and: (1) is removed from protocol therapy because of progressive disease where progressive disease is documented either by imaging studies or clinical progression; or (2) has at least one radiographic evaluation of disease status after the start of protocol therapy and is not electively removed from protocol therapy with s
Conditions Studied
Interventions
- OTHER pharmacological study
- DRUG trabectedin
Study Locations (14)
New York
- Roswell Park Cancer Institute - Buffalo
- New York University Langone Medical Center - New York
- Columbia University Medical Center - New York
Ontario
- Chedoke-McMaster Hospitals - Hamilton
- Hospital for Sick Children - Toronto
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- Children's Hospital Central California - Madera
Illinois
- Childrens Memorial Hospital - Chicago
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Ohio
- Nationwide Children's Hospital - Columbus
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT00070109 record still lists
NCT00070109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 188-participant average among 9 other Recurrent Ewing Sarcoma trials with a reported enrollment target (73% lower).
The record links to 5 conditions, with Recurrent Ewing Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which pharmacological study is the first listed.
NCT00070109 lists 14 locations in 11 states (New York, Ontario, Arkansas).
Frequently Asked Questions
What is clinical trial NCT00070109 about?
NCT00070109 is a clinical study titled "Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors". This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00070109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-01. Estimated completion is 2013-12.
What conditions does trial NCT00070109 study?
This clinical trial studies the following conditions: Recurrent Ewing Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor.
What interventions are being tested in trial NCT00070109?
The interventions under investigation include: pharmacological study (OTHER), trabectedin (DRUG).
Who is sponsoring clinical trial NCT00070109?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070109 being conducted?
This trial has 14 study locations across Arkansas, California, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00070109's enrollment target sits among peer trials
50 4th of 9 higher than 6 of 9 other Recurrent Ewing Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Ewing Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
ACTIVE NOT RECRUITING · Phase 2
-
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia